Healthcare >> CEO Interviews >> October 17, 2003

Martin Mcglynn – Stemcells Inc (stem)

MARTIN M. MCGLYNN joined StemCells, Inc., in January 2001 as its President and Chief Executive Officer and was elected to its Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson Ireland, Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and CEO of Pharmadigm, Inc., a privately held, venture capital backed startup company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC). Profile
TWST: Please give us a brief overview of StemCells, Inc.

Mr. McGlynn: StemCells, Inc. (STEM) is a publicly traded company quoted

on the NASDAQ. It was originally founded in 1995 by three icons